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Abstract
Background: Enterovirus 71 (EV71) infections manifest most commonly as a childhood exanthema known as hand-foot-and-
mouth disease (HFMD) and can cause neurological disease during acute infection.
Principal Finding: In this study, we describe the production, purification and characterization of EV71 virus produced from
Vero cells grown in a five-liter serum-free bioreactor system containing 5 g/L Cytodex 1 microcarrier. The viral titer was
.10
6 TCID50/mL by 6 days post infection when a MOI of 10
25 was used at the initial infection. Two EV71 virus fractions were
separated and detected when the harvested EV71 virus concentrate was purified by sucrose gradient zonal
ultracentrifugation. The EV71 viral particles detected in the 24–28% sucrose fractions had an icosahedral structure 30–
31 nm in diameter and had low viral infectivity and RNA content. Three major viral proteins (VP0, VP1 and VP3) were
observed by SDS-PAGE. The EV71 viral particles detected in the fractions containing 35–38% sucrose were 33–35 nm in size,
had high viral infectivity and RNA content, and were composed of four viral proteins (VP1, VP2, VP3 and VP4), as shown by
SDS-PAGE analyses. The two virus fractions were formalin-inactivated and induced high virus neutralizing antibody
responses in mouse immunogenicity studies. Both mouse antisera recognized the immunodominant linear neutralization
epitope of VP1 (residues 211–225).
Conclusion: These results provide important information for cell-based EV71 vaccine development, particularly for the
preparation of working standards for viral antigen quantification.
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Introduction
Enterovirus 71 (EV71) virus infection has recently caused
outbreaks of hand-foot-and-mouth disease (HFMD) associated
with severe neurological disease in young children [1,2] and has
become a serious public health problem in the Asia-Pacific region
[1,3–8] EV71 virus is a non-enveloped, single positive-stranded
RNA virus of the family Picornaviridae with a genome size of
approximately 7.4 kb. The EV71 virus is a pentameric icosahedral
particle consisting of 60 copies of the VP1, VP2, VP3 and VP4
capsid proteins. Although the host receptors for EV71 virus had
been identified [9,10], there is no effective antiviral agent to
combat EV71 infection. An effective vaccine is still the best
strategy to control and prevent the disease. Experimental EV71
vaccines [8,11] have included live-attenuated virus [12,13],
formaldehyde-inactivated virions [14,15], virus-like particles
[16], VP1 recombinant protein [17,18], VP1 DNA vaccine [19],
VP1 peptide-based vaccine [20,21], bacterial or viral vectors
expressing VP1 [17,22], and a Vero cell-adapted live attenuated
virus [13]. In previous murine immunogenicity studies, the
formalin-inactivated EV71 virus produced from Vero cells elicited
a more effective immune response than recombinant VP1 protein
or DNA vector vaccines [17,18]. These results are difficult to
compare because the standard production methods, standard virus
neutralization assays and methods used to quantify the critical
viral antigens are not available. Therefore, the production of pure
EV71 viral particles as a working standard is critical for EV71
vaccine development.
The semi-purified EV71 virion and EV71 virus like-particle
(VLP) can be generated from the harvested virus concentrate by
either precipitation with 30% polyethylene glycol or zonal
ultracentrifugation using either a 40–65% discontinuous sucrose
gradient or a 5–40% linear CsCl gradient [16,18,20], but
information about the purity and physical structure of these
virions is limited. In the present study, we describe the purification
and biophysical characterization of EV71 viral particles that were
produced from Vero cells grown in a serum-free microcarrier
bioreactor system.
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Ethics Statement
All experiments were conducted in accordance with the
guidelines of Laboratory Animal Center of NHRI. The animal
use protocols have been reviewed and approved by the NHRI
Institutional Animal Care and Use Committee (Approved protocol
No. NHRI-IACUC-098033-A).
Cells, culture medium and virus
African green monkey kidney (Vero) cells were kindly provided
by the Taiwan Centers of Disease Control (Taiwan CDC), which
obtained the original Vero cell line (passage #125) from the
American Type Culture Collection (ATCC). In general, Vero cells
were grown in serum-free VP-SFM medium (GIBCO), and cells
were passaged twice weekly in T-flasks. The E59 strain (genotype
B4), the clinical isolate of the EV71 virus, was obtained from the
Taiwan CDC. EV71/E59 virus stocks were collected from the
supernatants of infected Vero cells at three days post infection
(DPI). The titers of the virus stocks were determined by a plaque
assay, and the stocks were stored at 280uC.
EV71 virus cultivation using a bioreactor system
EV71 virus was cultivated using serum-free VP-SFM medium in
a BIOFLO 310 bioreactor (NBS, US) based on the microcarrier
cell culture bioprocess previously reported [15,23]. Bioreactor
culture medium containing 5 g per L Cytodex 1 was inoculated
with 2610
5 cells per mL, and the cell density reached 2 to 2.5610
6
cells per mL after six days of cultivation. The Vero cells were
infected with EV71/E59 at a MOI of 10
25. EV71/E59 virus
stocks were collected from the microcarrier culture supernatants at
6 to 8 days post infection.
EV71 virus purification by continuous sucrose gradient
ultracentrifugation
The EV71 virus culture supernatant was harvested from the
bioreactor culture. The cell debris was removed by passage
through a 0.65 mm filter (Sartorius), and the supernatant was
concentrated 20-fold with a 100 K TFF capsule (Pall). The crude
EV71/E59 concentrate (,200 mL from a 5 L run) was loaded
onto a 10–50% continuous sucrose gradient and centrifuged at
32,000 rpm for three hours using a zonal rotor in a Hitachi CP80
ultracentrifuge. The fractions (50 mL per fraction) at 20 to 40%
sucrose were collected and individually dialyzed against three
exchanges of 1 L PBS at pH 7.4 (Gibco), then stored at 4uC. The
infectivity of the purified virus fraction was assessed by a TCID50
assay. The fractions were also subjected to SDS-PAGE and
western blot analyses. The zonal centrifugation-purified EV71/
E59 virus was pooled and concentrated by diafiltration using an
Amicon 100 K tube (Millipore) and centrifuged at 3,0006g, then
stored at 4uC. The total protein concentration of the purified virus
fractions was determined by a BCA protein assay. Half of the
purified EV71 virus fractions (10 mL) was stored at 280uC in 0.5-
mL aliquots; the other half was inactivated by 0.2% (v/v) formalin
at 37uC for 3 days and stored at 4uC.
Determination of viral titer
Viral titers were determined using the median endpoint of the
tissue culture’s infectious dose (TCID50). Serially-diluted virus
samples (from 10
21 to 10
28) were added to Vero cells grown in 96-
well plates, and 10 replicate samples were used for each dilution.
The 96-well plates were incubated for six days at 37uC, and the
TCID50 values were measured by counting the cytopathic effects
(CPE) on infected Vero cells. The TCID50 values were calculated
by the Reed-Muench method [24].
SDS-PAGE analysis and Western blotting
SDS-PAGE analysis of the purified EV71/E59 virus fractions
was performed in a NuPAGE 4–12% Bis-Tris Gel (Invitrogen)
according to the protocol suggested by the manufacturer. For
immunoblotting, EV71 viral proteins were directly electrotrans-
ferred onto the PVDF membrane. The membrane was subse-
quently soaked overnight at 4uC in 5.0% skim milk in PBS. Each
membrane was incubated with PBS buffer containing one of two
diluted (1:1000) EV71-specific monoclonal antibodies: either
MAB979 (Chemicon International) or E1 (produced in-house).
Antibodies were bound for 2 hr at room temperature. The
membranes were then washed five times with 15 mL assay buffer.
Binding of the respective antibodies to the viral proteins was
detected by adding 2 mL PBS buffer containing a horseradish
peroxidase (HRP)-conjugated donkey anti-mouse secondary
antibody (Jackson ImmunoResearch) at a dilution of 1:10,000.
After1-hr incubation at room temperature, the membrane was
washed 6 times with assay buffer and blotted dry. The protein
bands were revealed by adding TMB substrate solution (KPL).
Mouse immunogenicity studies
Different concentrations of inactivated EV71 particles (5 and
25 mg) were adsorbed on 2 mL aluminum phosphate (3 mg of
aluminum) at room temperature for 3 hr before immunization.
One group of 6 female BALB/c mice (6–8 weeks old) were
immunized intramuscularly (i.m.) with 0.2 mL of the alum-
absorbed inactivated EV71 particles and were boosted twice with
the same dose at two week intervals after priming. The immunized
mice were bled one week after the final boost, and the serum was
collected and used to analyze virus neutralization.
Virus neutralizing assay
Serum samples were collected from immunized mice and
inactivated at 56uC for 30 min. Each serum sample was added to a
microtube and serially diluted two-fold with fresh cell culture
medium; 400 mL of a 200-TCID50 virus suspension was then
added to each tube containing 400 mL of serially diluted serum.
After incubation at 4uC for 18–24 hr, 100 mL of serially diluted
samples were added to the 96-well plates containing Vero cells.
The cultures in the 96-well plates were incubated for 7 days at
37uC, and the TCID50 values were measured by counting
cytopathic effects (CPE) in infected cells. The 50% neutralization
inhibition dose (ID50) was calculated as the reciprocal of the serum
dilution that yielded a 50% reduction in the viral titer using the
Reed-Muench method.
Characterization of EV71 viral particles by transmission
electron microscopy (TEM)
Inactivated EV71 particles were deposited on a Formvar-coated
and carbon-vaporized 200-mesh copper grid. The sample was kept
on the copper grid for 15 min at room temperature, and excess
sample was then removed with filter paper. After washing twice
with ddH2O, the copper grid was stained with 2% phosphotungs-
tic acid solution for 2 min, which was then removed with filter
paper. The stained grid was dried for 3 days and observed under a
Hitachi H-7650 electron microscope.
EV71 viral RNA detection by real-time PCR
Viral RNA was isolated from 250 mL purified EV71 particles
(40 mg total proteins by BCA analysis) using Trizol LS reagent
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precipitation, the RNA pellet was dissolved in RNA-Safeguard
reagent solution (GeneMark, Taiwan). The first cDNA strand was
synthesized in a reaction containing 6.6 mLd H 2O, 0.5 mM
dNTPs, 4 mL5 6 buffer, 200 U SuperScript
TM III reverse
transcriptase (Invitrogen), 120 ng random primers (Invitrogen),
40 units RNaseOUT recombinant RNase inhibitor (Invitrogen)
and 5 mL total RNA as the template material. The mix was
incubated at 50uC for 1 h followed by 15 min at 70uC to denature
the reverse transcriptase. Two units of E. coli RNase H (Fermentas,
USA) were added and incubated at 37uC for 20 minutes to
remove RNA complementary to the cDNA. The first cDNA
strand product was then diluted 10-fold in water for the real-time
PCR assay. A recombinant plasmid DNA carrying the EV71 VP1
gene was constructed for use in the standard curve for real-time
PCR. The full-length VP1 sequence was amplified from the EV71-
E59 genome by RT-PCR and cloned into the pGEM-T Easy
Vector (Promega, USA). The recombinant plasmid was propa-
gated in Escherichia coli DH5a competent cells and purified with the
Plasmid DNA kit (BioKit, Taiwan); the concentration of the
purified DNA was determined in a NanoDrop 2000c spectropho-
tometer (Thermo Fisher Scientific Inc., USA). The standard curve
was generated from 10-fold serial dilutions of the recombinant
plasmid from 2.2610
8 to 2.2610
2 copies. EV71 viral mRNA was
assessed by quantitative PCR analysis with the LightCyclerH 480
Real-Time PCR system and the EV71-specific primer pair
EVVP1F: 59-GGTACCCCACGTTTGGAGA-39 (620–638 bp)
and EVVP1R: 59-TAGGACACGCTCCATACTCAAG-39 (658–
679 bp) and probe set No. 2: CAGGAGAA (Cat. No.
04684982001) from the Roche Universal Probe Library Assay
Design Center (Roche). The real-time PCR was evaluated with the
MaximaH Probe qPCR Master Mix (Fermentas, USA). Each
reaction contained 1.0 mL 10-fold diluted cDNA, 0.1 mM each
EVVP1F and EVVP1R, 0.05 mM probe, 10 mL master reaction
mix, and water to a final volume of 20 mL. The data were
analyzed with LightCycler Software.
Peptide-ELISA
Fifty-seven overlapping synthetic peptides were synthesized
using Fmoc chemistry by Kelowna International Scientific Inc.
(Taipei Hsien, Taiwan) according to the sequence of the VP1
capsid protein of EV71. Each peptide contained 15 amino acids,
10 residues of which overlapped with the adjacent peptides. The
reactivity of the antibody to each synthetic peptide was analyzed
by an enzyme-linked immunosorbent assay (ELISA) according to
the protocol previously reported by Panezutti et al. [25].
Results
EV71 virus production using a serum-free microcarrier
bioreactor
To establish cell-based EV71 vaccine production, the previously
reported serum-free microcarrier culture process was used to
produce EV71 virus (18,34). Vero cells were amplified to 2.0–
2.5610
6 cells/mL on 5 g/L Cytodex 1 microcarrier in either a
1.4-L or 5-L working volume bioreactor and infected by EV71 at a
10
25 multiplicity of infection (MOI). During the infection phase,
the viral titers were determined by a TCID50 assay and found to
reach 10
6/mL at 6 days post infection (DPI); there was no increase
in viral titers in the 7
th and 8
th DPI. The low MOI can result in
slow kinetics of viral growth, but similar kinetics of viral growth
based on the viral titer (TCID50) were found in both sizes of
bioreactor. When the culture supernatants were harvested at
either the 6
th or 8
th DPI, a 0.65-mm filter was very efficient for the
removal of cell debris. In addition, 100 K and 300 K tangential-
flow filter (TFF) capsules were tested for filtrate concentration; the
100 K TFF capsule was more effective at removing host cell
proteins for downstream virus purification (data not shown).
EV71 virus purification using sucrose gradient
ultracentrifugation
Zonal ultracentrifugation of a continuous sucrose gradient (10 to
50%) at 32,000 RPM for 3 hr was used to purify EV71 virus from
the harvest concentrate described above. The viral titer and
protein concentration of each fraction (50 mL) were determined
by TCID50 and BCA assays, respectively. The results of three
different experiments are summarized in Figure 1. The highest
infectious viral titers were found in fractions 16 and 17 containing
35–38% sucrose, with viral titers reaching 5610
6 TCID50/mL
(Fig. 1A). Viral titers in the range of 10
4–10
5 TCID50/mL were
detected in other fractions. The viral proteins in each fraction were
separated by SDS-PAGE, and the VP2-specific monoclonal
antibody MAb 979 was used to verify the presence of EV71 virus
by western blot. EV71 antigens were detected in two regions of the
sucrose gradient (Fig. 1B). The first region that contained EV71
viral antigens was in fractions 8, 9 and 10, which contained 24–
28% sucrose and had a low infectivity with a viral titer of
approximately 10
3 TCID50/mL. The second antigenic region co-
located with the highest infectious EV71 viral fractions, 16 and 17,
which had viral titers of 10
6 TCID50/mL. The biochemical, viral
and immunological properties of these two types of viruses (i.e.,
empty/defective viral particles or E-particles and infectious viral
particles or F-particles) are defined below. To identify differences
between these two types of EV71 viral particles, fractions 10 and
16 were individually diafiltrated with PBS and concentrated to
5 mL as virus stocks. The protein concentrations of the virus stocks
of fractions 10 (E-particles) and 16 (F-particles) were 50 and
21.5 mg/mL, respectively. In six batches from the bioreactor, the
protein concentration of the E-particles was consistently higher
than that of the F-particles with a ratio of 7:3.
Biophysical characterization of EV71 viral particles by
transmission electron microscopy (TEM)
The physical structure of the EV71 viral particles in the virus
stocks of fractions 10 and 16 were revealed by TEM analysis. For
biosafety reasons, the purified virus stocks were individually
inactivated by formaldehyde solution (4000:1) at 37uC for 3 days.
After preparation as described in the Materials and Methods, both
samples were analyzed by TEM and found to have icosahedral
particle structure (Fig. 2). The E-particles in fraction 10 (Fig. 2A)
and F-particles (Fig. 2B) in fraction 16 were completely different.
The diameters of the viral particles were approximately 30–31 nm
and 33–35 nm for the E- and F-particles, respectively. The size of
the F-particle is very similar to that of the enteroviruses of the
Piconaviridae family [26–30]. In addition, TEM revealed that the
physical structure of the E-particle was not solid, and the
icosahedral capsid appeared to be empty (Fig. 2A). In contrast,
the F-particles in fraction 16 were solid particles (Fig. 2B). Analyses
described below demonstrated that these structural differences
could be due to the presence of different viral proteins and RNA
compositions.
The viral protein composition of EV71 viral particles
Both the sucrose gradient zonal ultracentrifugation and TEM
analysis demonstrated that there were two types of EV71 viral
particles produced by Vero cells grown in the serum-free
microcarrier bioreactor system. The viral proteins of the two
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The F-particles in fraction 16 contained four major protein bands
with molecular weights (MWs) of 33 kDa, 28 kDa, 27 kDa and
8 kDa (Fig. 3A), corresponding to enterovirus capsid component
proteins VP1 (33 kDa), VP2 (28 kDa), VP3 (27 kDa) and VP4
(8 kDa) based on their predicted protein sequences (Table 1). In-
gel tryptic digest of the protein bands (33 kDa, 28 kDa, 27 kDa
and 8 kDa) and analysis by MALDI-TOF spectrometry identified
the tryptic fragments as human enterovirus 71 viral proteins based
on sequences in NCBI Entrez.
The E-particles in fraction 10 contained three major protein
bands with MWs of 36 kDa, 33 kDa and 27 kDa (Fig. 3A). The
36 kDa band was identified as incompletely processed VP22VP4
(VP0) by mass spectrometry. Other high MW protein bands were
also observed in fraction 10. To confirm the identity of the 36 kDa
and high MW bands of the E-particle fraction, two EV71-specific
monoclonal antibodies were used to identify the viral proteins by
western blot. MAb979 is a commercially available monoclonal
antibody with specificity against VP2 that recognized the 36 kDa
band (VP0) and other high MW proteins in the E-particle fraction
and a 28 kDa band in the F-particle fraction (Fig. 3B). These
results suggest that the E-particles are composed of incompletely
processed viral capsid proteins. A trace amount of the VP0
polypeptide was also found in the F-particle fraction by western
blot (Fig. 3B). The E1 antibody is a VP1-specific monoclonal
antibody produced in-house that reacted with the 33 kDa protein
band in both fractions and some of the high MW protein bands
(.55 to 62 kDa) in the E-particle fraction in the western blot
analysis (Fig. 3C). Taken together, the results indicate that the two
viral particles have different protein compositions. The western
blot analyses indicated that the E-particle fraction was composed
of the incompletely processed VP1-related and VP2-related
proteins. In addition, the high MW proteins in fraction 10 that
did not react with MAb979 and E1 may be contaminants derived
from host cell proteins and are now being characterized in our
laboratory.
RT-PCR determination of the EV71 viral RNA content
As described above, the E-particle had low virus infectivity,
contained incompletely processed viral polypeptides, and was
considerably lighter than the F-particle based on the sucrose
gradient ultracentrifugation. Viral RNA was individually extracted
from both EV71 viral particles to confirm that the differences in
physical structure (empty and solid) of the two types of EV71
Figure 1. Purification of the EV71 virus by sucrose gradient zonal ultracentrifugation. The concentrated EV71 harvest stock was separated
into 25 fractions. A. The viral titer of each fraction was determined by a TCID50 assay. B. The EV71 antigens were detected by western blot using
MAb979. P means the positive control that is the formalin-inactivated EV71/E59 vaccine bulk produced by roller bottle method.
doi:10.1371/journal.pone.0020005.g001
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PLoS ONE | www.plosone.org 4 May 2011 | Volume 6 | Issue 5 | e20005Figure 2. Photographs of EV71 viral particles as analyzed by transmission electron microscopy. (A) Fraction 10 was empty and had a
defective particle (E-particle) structure. (B) Fraction 16 was full and had a solid particle (F-particle) structure. The bar represents 50 nm.
doi:10.1371/journal.pone.0020005.g002
Figure 3. The viral antigen composition of the EV71 viral particle was analyzed by SDS-PAGE and western blot. (A) Two different types
of EV71 viral particles were analyzed on a NuPAGE 4–12% Birs-Tris Gel. (B) EV71 viral proteins were detected by the MAb979 antibody. (C) EV71 viral
proteins were detected by the E1 antibody.
doi:10.1371/journal.pone.0020005.g003
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RNA contents were measured by quantitative RT-PCR using
specific primers to amplify a 60 bp region of the VP1 gene (Fig. 4).
The signal for the VP1 RNA of the F-particle (blue line in Fig. 4)
was detectable after 12 cycles of PCR. In contrast, the E-particle
(red line) gave a detectable signal only after 28 PCR cycles. The
approximate difference in the cycling threshold (DCt) value was at
least 16, and therefore there was at least a 65536-fold difference
between the RNA contents of the F-particle and E-particle,
indicating that the E-particle had a lower EV71 viral RNA content
than the F-particle. The low RNA content of the E-particle is
consistent with its low infectivity and empty physical appearance
in the TEM analysis.
Differences in virus packaging
The two EV71 viral particles were inactivated with formalde-
hyde (formalin) solution (4000:1), and modifications were detected
by western blot analysis. After formalin inactivation, the pattern of
EV71 viral proteins in each viral particle was revealed using
MAb979 and E1 monoclonal antibodies (Fig. 5). In the formalin-
treated E-particle, both antibodies revealed that the viral proteins
were cross-linked to form high MW protein complexes. In
particular, the Western blot derived from E1 antibody showed
that VP1-related proteins had extensive cross-linking (Fig. 5B, lane
2), and most likely the pentamer was covalently cross-linked
together because no protein bands below 200 kDa MW were
observed. In the formalin-inactivated F-particle, both MAB979
and E1 antibodies bound to VP1 and VP2 viral proteins within the
pentamer that were cross-linked to form diverse high MW protein
complexes (Fig. 5A&B, lane 4). The differences in the cross-linking
patterns revealed by monoclonal antibodies also suggest that there
Table 1. Summary of the predicted molecular weights (MW)
of the EV71-E59 viral proteins and incomplete processed viral
polypeptides [35].
EV71 antigen
Amino acid
sequence Residues
Predicted
MW (kDa)
Viral antigen expected in the EV71 virion
VP4 1–69 69 8
VP2 70–323 254 28
VP3 324–565 242 27
VP1 566–862 297 33
Incomplete processed viral polypeptides
VP0 (VP4+VP2) 1–323 323 36
VP4+VP2+VP3 1–565 565 63
VP2+VP3 70–565 496 54
VP3+VP1 324–862 538 59
P1 (VP4+VP2+VP3+VP1) 1–862 862 95
doi:10.1371/journal.pone.0020005.t001
Figure 4. EV71 viral RNA content measured by RT-PCR. The results of quantitative RT-PCR using primers specific for a 60 bp region of the EV71
VP1 gene are reported for the F-particle and E-particle by the blue line and red line, respectively.
doi:10.1371/journal.pone.0020005.g004
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defective E-particles.
Mouse immunogenicity studies of EV71 viral particles
We next investigated whether these two types of formalin-
inactivated viral particles generated different types of immune
responses. Five groups of mice were immunized with different
amounts of the inactivated particles formulated with 300 mg Alum
and boosted with the same dosage after 2 weeks. With the
exception of group A (PBS control), antisera from all of the groups
of mice had virus neutralization titers against the EV71/E59 virus
(Table 2). The formalin-inactivated F-particle induced a higher
virus neutralizing antibody response in the mouse model than did
the inactivated E-particle. The current results from groups D & E
(Table 1) indicate that 1 mg of F-particle may induce the
maximum virus neutralizing antibody responses in the mouse
model. The low dosage (0.5 mg) of the E-particle (group B) elicited
a 5- to 10-fold lower virus neutralization titer than was observed in
the other groups (p,0.05). At the high dose (2.5 mg), the defective
EV71 viral particle induced a virus neutralizing antibody response
that was almost 2-fold less potent than that induced by the low
dosage of the F-particle (groups C and D in Table 2). Therefore,
we conclude that the formalin-inactivated F-particle is more
potent than the E-particle in the virus neutralizing antibody
responses.
Linear immunodominant epitope mapping
We also evaluated whether the two types of particles generated
a different spectrum of antibodies that recognized different linear
immunodominant epitopes. The antisera of groups C and E were
screened by peptide-ELISA for their reactivity with 57 overlapping
synthetic peptides that covered the entire VP1 protein. Both
antisera reacted solely with the VP1-43 peptide corresponding to
residues 211–225 (FGEHKQEKDLEYGAC), which was previ-
ously identified as the immunodominant linear neutralization
epitope in other studies [20,21]. Although the immune potency of
the two viral particles is different, they generate antibodies that
recognize the same linear immunodominant neutralization epitope
with similar titer (.1/12,800) in the mouse model.
Discussion
Several experimental EV71 vaccine candidates are being
developed, and encouraging mouse immunogenicity results have
been obtained when the prototype vaccine candidates were tested
at the preclinical level [for reviews see references 8 and 11].
Currently, inactivated whole-virion EV71 vaccines appear to be
the most potent vaccine candidates; however, immunological
results are difficult to compare because the standard production
methods, standard virus neutralization assays and the methods
used to quantify the critical viral antigens are not available. The
whole virion EV71 vaccine was produced by very crude methods,
and the downstream purification process and the risk of
contamination by host cell proteins were not investigated
[14,15,23]. Therefore, the biochemical, biophysical and immuno-
logical characterizations of purified EV71 viral particles were
performed in this study. In addition, we also evaluate whether the
purified EV71 viral particles could be used as working standards
for EV71 vaccine development. In the current study, a serum-free
microcarrier Vero cell culture system for EV71 virus production
was established using a low multiplicity of infection (MOI) to
minimize virus seed usage, which could easily be adapted to a
large-scale bioreactor process. The low MOI (10
25) did not reduce
the EV71 viral titer (5610
6 TCID50). Serum-free medium was
used to avoid problems associated with bovine serum, such as lot-
to-lot inconsistency, potential prion contamination and the
difficulty of removing the high serum protein content during
downstream purification steps.
In this study, two types of EV71 viral particles (E- and F-
particles) were produced from a serum-free Vero cell microcarrier
bioreactor system and separated and purified using continuous
sucrose gradient ultracentrifugation. These results are very similar
to those of poliovirus studies in which two different polio viral
particles were isolated and identified by sucrose density centrifu-
gation [29]. Two types of poliovirus structures (D- and C-antigens)
were observed and characterized by electron microscopy and
biochemical assays. The D-antigen, like the F-particle in this study,
had a high viral RNA content and a full particle structure. In
contrast, the C-antigen lacked RNA content and had an empty
Figure 5. Western blot analyses of EV71 viral particles
inactivated by formaldehyde. The two different types of formalin-
inactivated EV71 particles were separated on a NuPAGE 4–12% Bis-Tris
Gel and analyzed by two monoclonal antibodies: (A) the MAb979
antibody and (B) the E1 antibody.
doi:10.1371/journal.pone.0020005.g005
Table 2. EV71 virus neutralization titers of mouse antisera
generated against two different types of EV71-E59 viral
particle fractions as measured by a TCID50 neutralization
assay.
Group Sample
Total
protein (mg)
TCID50 neutralization
titer (GMT ± SE)
A PBS 0 ,20
B E-particles 0.5 1886105
C E-particles 2.5 9066351
D F-particles 0.5 16046533
E F-particles 2.5 20206799
doi:10.1371/journal.pone.0020005.t002
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study. When we compared the total protein yield of these EV71
viral particles from the six batches from the bioreactor, the ratio of
the E-particle to the F-particle was consistently 7:3. We are
currently investigating the parameters (altering MOI, culture
conditions, harvest times, etc.) of the Vero cell culture that
influence the formation of the E-particle.
The two EV71 particles had similar icosahedral structures, but
their sizes were slightly different, 31–33 nm and 33–35 nm for the
E-particle and F-particle, respectively. This size difference is most
likely due to differences in the composition of the viral protein
components and the viral RNA contents as described above.
Generally, the morphogenesis of the Picornaviridae virus begins with
the freshly translated P1 polypeptide forming the promoter for self-
assembly into a pentamer unit, followed by formation of the empty
capsid shell by additional pentamers. The pre-virion and virion
formation requires the specific cleavage of the P1 polypeptide [31].
The P1 polypeptide is cleaved into the VP0, VP1 and VP3
proteins by the viral non-structural protein, 3CD protease. The
VP0 protein is then cleaved into VP2 and VP4 by autocatalytic
action that involves the viral RNA [26]. Based on the SDS-PAGE
and western blot analyses, the E-particle was an immature particle
in which the VP0 protein (VP2+VP4) was incompletely processed.
The components of the E-particle were very similar to those of the
C-antigen of poliovirus [31]. Some high MW protein bands (60 to
70 kDa) were detected in the E-particle, indicating that the P1
polypeptide was most likely incompletely processed during viral
assembling and packaging. In addition, potential cleavage sites
were predicted in the P1 polypeptide that could generate different
sizes of viral proteins [32]; http://www.cbs.dtu.dk/services/
NetPicoRNA/). Our results indicate that the immature capsid
constructed by incompletely processed viral proteins can still form
the icosahedral particle structure. The trace amount of VP0 found
in the F-particle fraction supports cleavage of the VP0 protein into
VP2 and VP4 by autocatalytic action involving viral RNA [26].
Quantitative RT-PCR studies of the VP1 gene content suggest
that the EV71 viral RNA was packaged into the immature capsid
to form the defective E-particles. The approximate difference in
the cycling threshold (DCt) value was 16, indicating there was at
least a 10,000-fold lower RNA content in the E-particle than in the
F-particle. The low RNA content of the E-particle is consistent
with its low infectivity and the empty physical appearance
observed by TEM.
Formalin inactivation was performed to further confirm the
differences in the physical structures of the two types of EV71
particles for vaccine production. Formalin-inactivated vaccines
have been effective by cross-linking the primary amino groups in
the proteins with aldehyde and other nearby nitrogen atoms. The
different cross-linking patterns of the capsid proteins after formalin
inactivation suggest that the conformations and interactions of the
viral proteins within the pentamer of the E- and F-particles are
likely different. This difference in particle structure and the
interactions between the viral proteins are not easily observed by
TEM. Differences in conformation were also observed in non-
infectious empty particles and infectious viral particles of type 3
poliovirus [27].
The ability of the formalin-inactivated defective EV71 E-
particle to induce neutralizing antibody responses in the mouse
immunogenicity study is very different from that of the poliovirus
C-antigen. The C-antigen could not induce neutralizing antibod-
ies in poliovirus vaccine murine immunogenicity studies [27,30].
The particle configuration of the C-antigen was different than that
of the D-antigen, which influenced the display of antigenic sites
[27]. The main antigenic sites have been identified as conforma-
tional and are located in the VP1, VP2 and VP3 regions of
poliovirus [33]. These findings are also different from EV71 virus.
The important murine immunodominant linear epitopes of EV71
have been identified as residues 208–222 and 240–260 of the VP1
capsid protein [20,21,34]. The synthetic peptides SP55 and SP70
corresponding to residues 163–177 and 208–222 of VP1,
respectively, elicited neutralizing antibodies against EV71 infec-
tion [20,21]. The neutralizing antibodies induced by the formalin-
inactivated E-particles were less potent than the formalin-
inactivated F-particle in a virus neutralization assay, but
interestingly antibodies generated from both particles recognized
the same immunodominant linear neutralization epitope of VP1
reported previously (residues 211–225). The results indicate that
the configuration of the EV71 E-particle may not be different
enough to influence the important antigenic and immunogenic
sites. To be cost-effective the E-particles of EV71 could be
considered as an additional antigen to the F-particles for EV71
vaccine development since the content of E-particles is at least 2-
fold more than the F-particles in the final production yield. In
conclusion, the current findings and the full characterization of the
EV71 viral particles provide valuable information for the
development of cell-based formalin-inactivated EV71 vaccine, in
particular the F-particles could be used in a standardized assay for
EV71 antigen quantification.
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